Skeptical briefing documents pertaining to the U.S. FDA’s adcom meeting on Y-mabs Therapeutics Inc.’s Omblastys (131I-omburtamab) turned out predictive of the less-than-happy outcome, as the regulator’s Oncologic Drugs Advisory Committee (ODAC) turned thumbs down on the prospective drug for pediatric central nervous system/leptomeningeal metastasis from neuroblastoma.
Briefing documents related to the Oct. 28 meeting of the Oncologic Drugs Advisory Committee (ODAC) to deliberate over Y-mabs Therapeutics Inc.’s Omblastys (131I-omburtamab) took aim at the company’s ongoing, pivotal experiment called Study 101, data from which the company highlighted in early October.
Ariceum Therapeutics GmbH is picking up where Ipsen SA left off and taking forward the targeted radiopharmaceutical drug satoreotide, developed by the French pharma to phase II but subsequently divested when it ditched its radiation therapy portfolio.
An international study led by U.S. oncologists at Children's Hospital of Philadelphia has successfully used a new antibody discovery platform developed by Myrio Therapeutics of Melbourne, Australia, to help identify and target key drivers of neuroblastoma in mouse models, the authors reported in the November 3, 2021, issue of Nature.
The largest single cell transcriptomics study of neuroblastoma to date has discovered that this childhood cancer arises from a single type of embryonic cell, the sympathoblast.
